Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

Author:

Key Nigel S.1,Khorana Alok A.2,Kuderer Nicole M.3,Bohlke Kari4,Lee Agnes Y.Y.5,Arcelus Juan I.6,Wong Sandra L.7,Balaban Edward P.8,Flowers Christopher R.9,Francis Charles W.10,Gates Leigh E.11,Kakkar Ajay K.12,Levine Mark N.13,Liebman Howard A.14,Tempero Margaret A.15,Lyman Gary H.16,Falanga Anna17

Affiliation:

1. University of North Carolina, Chapel Hill, NC

2. Cleveland Clinic, Cleveland, OH

3. Advanced Cancer Research Group and University of Washington, Seattle, WA

4. American Society of Clinical Oncology, Alexandria, VA

5. BC Cancer Agency, Vancouver, British Columbia, Canada

6. University of Granada, Granada, Spain

7. Dartmouth-Hitchcock Medical Center, Lebanon, NH

8. Penn State Cancer Institute, Hershey, PA

9. Emory University, Atlanta, GA

10. James P Wilmot Cancer Center and University of Rochester, Rochester, NY

11. Patient Representative, Denver, CO

12. Thrombosis Research Institute and University College, London, United Kingdom

13. McMaster University, Hamilton, Ontario, Canada

14. University of Southern California and Norris Comprehensive Cancer Center, Los Angeles, CA

15. University of California, San Francisco, San Francisco, CA

16. Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA

17. Hospital Papa Giovanni XXIII, Bergamo; and University of Milan Bicocca, Milan, Italy

Abstract

PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs published from August 1, 2014, through December 4, 2018. ASCO convened an Expert Panel to review the evidence and revise previous recommendations as needed. RESULTS The systematic review included 35 publications on VTE prophylaxis and treatment and 18 publications on VTE risk assessment. Two RCTs of direct oral anticoagulants (DOACs) for the treatment of VTE in patients with cancer reported that edoxaban and rivaroxaban are effective but are linked with a higher risk of bleeding compared with low-molecular-weight heparin (LMWH) in patients with GI and potentially genitourinary cancers. Two additional RCTs reported on DOACs for thromboprophylaxis in ambulatory patients with cancer at increased risk of VTE. RECOMMENDATIONS Changes to previous recommendations: Clinicians may offer thromboprophylaxis with apixaban, rivaroxaban, or LMWH to selected high-risk outpatients with cancer; rivaroxaban and edoxaban have been added as options for VTE treatment; patients with brain metastases are now addressed in the VTE treatment section; and the recommendation regarding long-term postoperative LMWH has been expanded. Re-affirmed recommendations: Most hospitalized patients with cancer and an acute medical condition require thromboprophylaxis throughout hospitalization. Thromboprophylaxis is not routinely recommended for all outpatients with cancer. Patients undergoing major cancer surgery should receive prophylaxis starting before surgery and continuing for at least 7 to 10 days. Patients with cancer should be periodically assessed for VTE risk, and oncology professionals should provide patient education about the signs and symptoms of VTE. Additional information is available at www.asco.org/supportive-care-guidelines .

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 1081 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3